(Reuters) - Merck & Co’s (MRK.N) quarterly profit and sales beat forecasts as strong demand for the company’s diabetes and asthma drugs offset a sharp decline for its Remicade arthritis drug.
The No. 2 U.S. drugmaker said on Friday it earned $1.69 billion, or 55 cents per share, in the third quarter. That compared with $342 million, or 11 cents per share, in the year-ago period, when the company took several big charges.
Excluding special items, Merck earned 94 cents per share. Analysts on average expected 91 cents per share, according to Thomson Reuters I/B/E/S.
Global revenue rose 8 percent to $12.02 billion, topping Wall Street expectations of $11.61 billion.
Reporting by Ransdell Pierson; Editing by Derek Caney